Background {#Sec1}
==========

Secondary brain injury associated with elevated intracranial pressure (ICP) is an important cause of mortality and morbidity in patients with severe traumatic brain injury (TBI) \[[@CR1]\]. Therefore, identifying high ICP and optimizing its management is believed to be critically important. Yet, no definitive evidence exists on how ICP should be monitored and treated \[[@CR2]\]. Patient and treatment heterogeneity make conducting randomized controlled trials (RCTs) challenging. On one hand, the majority of RCTs done to date have produced nonsignificant findings \[[@CR3]\]. On the other hand, observational studies, which are easier to conduct, are at risk for confounding by indication, hampering causal inference \[[@CR4], [@CR5]\].

In the absence of conclusive evidence, treatment policy is usually based on local practices, individual preferences, and resource availability \[[@CR6]--[@CR9]\]. It is likely that centers and practitioners individually balance potential benefits and risks of different ICP management strategies, which may result in some centers being relatively aggressive and others being more conservative in their treatment policies.

A novel and promising approach in estimating treatment effectiveness is to exploit the existing variation by comparing standard practices between different centers or countries, which is referred to as comparative effectiveness research (CER) \[[@CR10], [@CR11]\]. The Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study (grant 602150) is currently recruiting and will use CER methodology to study treatment effectiveness of ICP management \[[@CR10]\]. As a first step, we examined self-perceived practices of ICP monitoring and associated treatment policies by sending a survey to the centers participating in the CENTER-TBI study. Because previous European survey studies that addressed ICP management were published more than 10 years ago \[[@CR12], [@CR13]\], this study will provide an up-to-date overview of ICP management in Europe. Topics identified as showing substantial between-center variation that are plausibly associated with patient outcome will be selected for CER, and their treatment effectiveness can be studied once the CENTER-TBI patient-level data become available.

Methods {#Sec2}
=======

Study sample {#Sec3}
------------

All centers participating in the prospective, longitudinal, observational CENTER-TBI study (<https://www.center-tbi.eu/>) were asked to complete a set of questionnaires on structures and processes of care for patients with TBI. Questionnaires were sent to 71 centers in 20 countries between 2014 and 2015 \[[@CR14]\]. Three centers dropped out of the CENTER-TBI study, resulting in 68 eligible centers from Austria (*n* = 2), Belgium (*n* = 4), Bosnia and Herzegovina (*n* = 2), Denmark (*n* = 2), Finland (*n* = 2), France (*n* = 7), Germany (*n* = 4), Hungary (*n* = 2), Israel (*n* = 2), Italy (*n* = 9), Lithuania (*n* = 2), Latvia (*n* = 3), The Netherlands (*n* = 7), Norway (*n* = 2), Romania (*n* = 1), Serbia (*n* = 1), Spain (*n* = 4), Sweden (*n* = 2), the United Kingdom (*n* = 9), and Switzerland (*n* = 1).

Questionnaire development and administration {#Sec4}
--------------------------------------------

A set of questionnaires designed to measure structure and process of TBI care was developed on the basis of available literature and expert opinion. These questionnaires were comprehensively described in a previous publication \[[@CR14]\]. Pilot testing was undertaken in 16 of the participating centers, and feedback was incorporated into the final questionnaire design.

One of the questionnaires contained 29 questions on ICP monitoring and treatment at the intensive care unit (ICU) (Additional file [1](#MOESM1){ref-type="media"}). In most questions, we explicitly asked for the "general policy," which was defined as the treatment or monitoring modality estimated to be used in more than 75% of patients, recognizing that there might be exceptions. In some questions, we asked for quantitative estimations. The representatives of the centers could indicate how often they used a particular monitoring or treatment strategy (never = 0--10%, rarely = 10--30%, sometimes = 30--70%, frequently = 70--90%, always = 90--100%). The options "frequently" and "always" were interpreted as representing the general policy, in line with a previous report \[[@CR15]\]. All definitions used in the questionnaire are described in Additional file [2](#MOESM2){ref-type="media"}.

Analyses {#Sec5}
--------

We calculated frequencies and percentages for all variables related to the number of responders for that variable. We examined factors associated with a relatively aggressive ICP monitoring and treatment strategy with the chi-square test or Fisher's exact test as appropriate. Centers were classified as being relatively aggressive if they (a) place an ICP monitor in patients with a Glasgow Coma Scale (GCS) score ≤ 8 and an abnormal head computed tomographic (CT) scan, and (b) if they generally perform at least one of three second-tier treatments that represent a maximum therapy intensity (barbiturates, decompressive craniectomy, and hypothermia \< 35 °C) \[[@CR16]\].

We examined whether there were differences between and within geographic regions in the use of first- and second-tier treatments. Countries were divided into seven geographic regions (Northern Europe, Western Europe, United Kingdom, Southern Europe, Eastern Europe, Baltic states, and Israel). Within each region, we examined the percentage of centers which indicated that the particular treatment was their general policy. In addition, we assessed the influence of geographic region on treatment decision by performing logistic regression analysis with treatment as the dependent variable (general policy yes/no) and geographic region (categorical variable) as an independent variable. The Nagelkerke *R* ^2^ was reported, representing the proportion of variation in treatment that can be explained by geographic region. Analyses were performed using IBM SPSS Statistics version 21 software \[[@CR17]\].

Results {#Sec6}
=======

Participating centers {#Sec7}
---------------------

Sixty-six centers (97% response rate) completed the questionnaire on ICP monitoring and treatment in patients with severe TBI. Questionnaires were completed mainly by intensive care physicians (*n* = 33, 50%) and neurosurgeons (*n* = 23, 35%). Most centers (*n* = 60, 91%) had an academic affiliation, and 44 (67%) were designated level I trauma centers (*see* Additional file [2](#MOESM2){ref-type="media"} for definitions). Centers had a median of 33 (IQR 22--44) ICU beds in total and treated a median of 92 (IQR 52--160) patients with severe TBI annually. Forty-three (65%) centers had adopted a "closed" ICU model, which is defined as an ICU model where a critical care physician (intensivist) is primarily responsible for the delivery of care for patients at the ICU \[[@CR18]\]. An "open" model, defined as an ICU model where the admitting physician (e.g., neurosurgeon) is primarily responsible for the care of ICU patients, was adopted in three (5%) centers \[[@CR18]\]. A "mixed" model, which is an ICU model where the admitting physician is primarily responsible but the care is provided by a critical care physician, was adopted in 20 (30%) centers. Approximately half (*n* = 39) of the centers had a dedicated neurosciences ICU. Approximately three-fourths of sites (*n* = 49, 74%) indicated that they used the 2007 Brain Trauma Foundation (BTF) guidelines or institutional guidelines that were based on the BTF guidelines.

Indications for ICP monitoring {#Sec8}
------------------------------

The majority of participants (*n* = 58, 91%) indicated that they would generally place an ICP monitor in patients with GCS ≤ 8 and CT abnormalities (Fig. [1](#Fig1){ref-type="fig"}). ICP monitors were less often considered for other indications, such as GCS ≤ 8 without CT abnormalities (*n* = 15, 23%), inability to assess a patient with CT abnormalities clinically (e.g., due to sedatives; *n* = 11, 17%), and intraventricular hemorrhage (*n* = 21, 33%). Around one-third of the participants would place an ICP monitor in patients with polytrauma (GCS \> 8) who require extracranial surgery or mechanical ventilation but would not otherwise have an indication for ICP monitoring. Patient-specific reasons for not monitoring ICP included when the risk of raised ICP was considered low (*n* = 40, 62%), patients were considered unsalvageable (*n* = 37, 57%), or GCS was \> 8 (*n* = 37, 57%) (Additional file [2](#MOESM2){ref-type="media"}).Fig. 1Indications for ICP monitoring placement. Shown are the percentages of centers that indicated that they would generally place an ICP monitor in patients with the described characteristics. Question was completed by 64 of 66 centers. *CT* Computed tomographic, *GCS* Glasgow Coma Scale, *ICP* Intracranial pressure

Variability in monitoring and treatment of intracranial hypertension {#Sec9}
--------------------------------------------------------------------

There is large variation in monitoring and treatment characteristics among European centers treating patients with TBI (Fig. [2a and b](#Fig2){ref-type="fig"}).Fig. 2**a** Algorithm for ICP management: ICP monitoring. The *blue box* represents ICP monitoring with the policy of parenchymal monitor on the left and ventricular catheter on the right. *Orange boxes* are checkpoints during the ICP monitoring process. The *N* value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. ^1^ Centers that indicated these situations as the top one of the top three reasons for choosing a ventricular or parenchymal catheter. ^2^ Frequently and always summed. ^3^ Arterial blood pressure, midauricular level, ventricular motor, not applicable (we use only parenchymal monitors), room air, calibrated by device and meatus externa. ^4^ Prior to insertion of ventricular catheter for ICP monitoring. ^5^ Depending on other factors, such as the use of platelet aggregation inhibitors. ^6^ Multiplate and rotational thromboelastometric analysis prior to surgery if concerns. **b** Algorithm for ICP management: treatment indications, first- and second-tier treatment. The *red box* represents ICP treatment with first-tier treatment on *top* and second-tier treatment at the *bottom. Orange boxes* are checkpoints during the ICP treatment process. The *N* value represents the number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the number of centers that completed this question. ^1^ Decompressive craniectomy is (almost) never performed in our hospital. ^2^ Multiple answers were possible. ^3^ Only if ventricles are enlarged. ^4^ Frequently and always summed. ^5^ Clonidine or dexmedetomidine. ^6^ Sufentanil (4), remifentanil (2), β-blockers (1), alfentanil (2), esketamine (1). ^7^ Standard continuous infusion. ^8^ PaCO~2~ \< 30 mmHg. ^9^ Variable, depends on patient. ^10^ Variable, depends on physician. *CPP* Cerebral perfusion pressure, *CSF* Cerebrospinal fluid, *EEG* Electroencephalogram, *HS* Hypertonic saline, *ICP* Intracranial pressure, *INR* International normalized ratio, *IV* Intravenous, *PaCO* ~*2*~ Partial pressure of carbon dioxide

### Parenchymal and ventricular ICP devices {#Sec10}

Both parenchymal and ventricular ICP devices were available in more than half of centers (*n* = 38, 59%). One-third (*n* = 21) of the participants indicated that they used only parenchymal monitors, whereas five (8%) participants indicated that they used only ventricular catheters. In centers that used both types of monitors, parenchymal monitors were typically used routinely, with ventricular catheters placed either when the ventricles were enlarged or when cerebrospinal fluid (CSF) drainage was indicated. When a ventricular drain was used, half of the participants indicated that their local practice was generally to leave the drain open (*n* = 19, 50%), and the other half indicated a policy of intermittent drainage (*n* = 19, 50%) (Fig. [2a](#Fig2){ref-type="fig"}).

### Precautions with ICP monitor placement {#Sec11}

Half of the participants (55% ventricular catheter and 43% parenchymal sensor) indicated that they generally administered prophylactic antibiotics prior to the insertion of an ICP monitor, which was continued in around 10% of the centers. The majority of participants (*n* = 50, 77%) generally assessed the patient's coagulation status prior to ICP monitor insertion. There was wide variability regarding the minimum international normalized ratio and minimum platelet count considered safe for device insertion (Fig. [2a](#Fig2){ref-type="fig"}).

### Additional neuromonitoring {#Sec12}

Half of the participants (*n* = 33) indicated that they generally used at least one additional neuromonitoring device (Additional file [2](#MOESM2){ref-type="media"}). Transcranial Doppler was generally applied in 24 (38%) centers, and brain tissue oxygenation was used in 12 (19%) centers.

### First-tier treatment of elevated ICP {#Sec13}

The majority of participants indicated an ICP threshold for medical treatment \> 20 mmHg (*n* = 54, 83%) (Fig. [2b](#Fig2){ref-type="fig"}). There was less consensus on cerebral perfusion pressure (CPP) treatment thresholds; 39 participants (59%) indicated a threshold of 60 mmHg in their center, whereas 25 (38%) indicated individualized CPP targets.

Propofol (*n* = 54, 83%), midazolam (*n* = 48, 75%), fentanyl (*n* = 37, 58%), and morphine (*n* = 32, 51%) were generally used as part of first-tier treatment in patients with elevated ICP, whereas the use of α~2~-agonists (*n* = 10, 16%) and barbiturates (*n* = 12, 19%) was less frequent (Fig. [2b](#Fig2){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}). Neuromuscular blocking agents were generally used in 16 (25%) centers. Participants typically preferred a specific combination of sedatives and analgesics as part of first-tier treatments: 50 participants (76%) indicated they used two to four of eight sedatives and analgesics as general policy and the other interventions only infrequently (Additional file [2](#MOESM2){ref-type="media"}).

Regarding the use of osmotic therapy, two-thirds of the participants indicated generally using mannitol (*n* = 43, 65%) and/or hypertonic saline (*n* = 44, 67%). Seventeen participants indicated the use of mannitol, but not hypertonic saline, as their general policy, whereas 18 participants indicated the opposite. Fourteen (22%) participants indicated generally using hypertonic saline in conjunction with mannitol (Fig. [2b](#Fig2){ref-type="fig"}). Crystalloids were the most commonly used intravenous fluids to augment CPP (*n* = 60, 91%), whereas other fluids (starches, albumin, and other combinations) were less often used (12--23%). Vasopressors were generally used in almost all centers to support CPP (*n* = 63, 96%). Among the parameters used to titrate vasoactive drugs, mean arterial pressure targets (*n* = 51, 77%) and transpulmonary thermodilution monitoring by means of pulse contour cardiac output (*n* = 35, 53%) were most often used (Additional file [2](#MOESM2){ref-type="media"}).

### Second-tier treatments for refractory intracranial hypertension {#Sec14}

Among the second-tier treatments, decompressive craniectomy (*n* = 26, 39%), barbiturates (*n* = 21, 32%), and CSF drainage (*n* = 22, 33%) were the most often employed (Fig. [2b](#Fig2){ref-type="fig"}). Hypothermia and hyperventilation (partial pressure of carbon dioxide \< 30 mmHg) were the general policy in 24.6% and 15.4% of the centers, respectively, whereas approximately one-third of the participants indicated never using hypothermia and hyperventilation (Additional file [2](#MOESM2){ref-type="media"}). Participants typically preferred one (*n* = 27, 42%) or two (*n* = 20, 31%) second-tier treatments and indicated use of the other options infrequently (Additional file [2](#MOESM2){ref-type="media"}). Details on indication, administration, and targets of second-tier treatments are presented in Additional file [2](#MOESM2){ref-type="media"} and show a high degree of variability.

Factors associated with aggressive monitoring and treatment policies {#Sec15}
--------------------------------------------------------------------

Around half of the centers were classified as using an aggressive ICP monitoring and treatment policy (*n* = 32, 48%). Centers with an open or mixed ICU model more often applied an aggressive ICP management style in comparison to centers with a closed ICU model (*p* = 0.05). We did not find significant associations between aggressiveness and any of the other factors studied (Table [1](#Tab1){ref-type="table"}).Table 1Factors associated with an aggressive ICP management styleFactorRelatively aggressive centers (*n* = 32)Relatively conservative centers (*n* = 34)*p* ValueICU organization0.05 Closed17 (40%)26 (60%) Open/mixed15 (65%)8 (35%)Dedicated neurosciences ICU0.96 Available19 (49%)20 (51%) Not available13 (48%)14 (52%)BTF guidelines used^a^0.48 Yes25 (51%)24 (49%) No7 (41%)10 (59%)Volume^b^0.82 High volume17 (47%)19 (53%) Low volume15 (50%)15 (50%)Country's income level^c^0.83 High income27 (49%)28 (51%) Relatively low income5 (46%)6 (54%)Geographic location^d^0.84 Northern Europe4 (44%)5 (56%) Western Europe13 (52%)15 (48%) United Kingdom3 (43%)4 (57%) Southern Europe5 (42%)7 (58%) Baltic states2 (40%)3 (60%) Eastern Europe3 (50%)3 (50%) Israel2 (100%)0 (0%)*BTF* Brain Trauma Foundation, *ICU* Intensive care unit^a^ BTF guidelines or institutional guidelines that were broadly based on the BTF guidelines^b^ Relatively high volume (number of patients with severe TBI admitted to the ICU higher than the median number of patients with severe TBI admitted to the ICU \[*n* = 92\]) vs. relatively low volume (number of patients with severe TBI admitted to the ICU lower than or equal to the median number of patients with severe TBI admitted to the ICU)^c^ The division into relatively high- and low-income countries was based on a 2007 report by the European Union \[[@CR21]\]. High income = Austria, Belgium, Denmark, Finland, France, Germany, Israel, Italy, The Netherlands, Norway, Spain, Sweden, United Kingdom, and Switzerland; relatively low income = Bosnia and Herzegovina, Bulgaria, Hungary, Latvia, Lithuania, Romania, and Serbia^d^ Northern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania

Influence of geographic region on treatment decisions {#Sec16}
-----------------------------------------------------

The use of first- and second-tier treatments varied substantially within and between geographic regions (Table [2](#Tab2){ref-type="table"}). Morphine and CSF drainage showed the largest within-region variation, with approximately half of the participants within each region stating they generally use these treatments. Between-region differences were especially pronounced for barbiturates as first-tier treatment. Barbiturates were used mainly in the Baltic states and Eastern Europe, and geographic region explained 63% of the variance in barbiturate use. In addition, the use of mannitol varied substantially across regions, with all participants in the Baltic states, Eastern Europe, and Israel indicating they generally use mannitol, whereas only 11% of the participants in Northern Europe stated they generally use mannitol. In Northern Europe, Western Europe, and the United Kingdom, propofol, midazolam, morphine, and hypertonic saline are generally applied as first-tier treatment, whereas participants in Southern Europe, the Baltic states, and Eastern Europe also indicated they generally use fentanyl, barbiturates, CSF drainage, and mannitol.Table 2Within- and between-region variation in first- and second-tier treatments for elevated intracranial pressureVariableNorthern Europe (*n* =9)Western Europe (*n* = 25)United Kingdom (*n* =7)Southern Europe (*N* =12)Baltic states (*n* = 5)Eastern Europe (*n* = 6)Israel (*n* = 2)Nagelkerke *R* ^2^ valueFirst-tier treatments Propofol78%76%100%92%80%67%100%0.14 Midazolam67%76%29%75%100%83%100%0.22 Fentanyl44%44%29%67%100%100%50%0.31 Morphine56%48%57%50%40%33%50%0.02 Neuromuscular blocking agents0%16%29%25%40%67%50%0.25 α~2~-Agonists33%12%0%17%40%0%0%0.22 Barbiturates11%8%0%0%80%83%0%0.63 CSF drainage33%24%0%25%60%50%0%0.20 Mannitol11%67%43%83%100%100%100%0.46 Hypertonic saline89%71%86%58%40%33%100%0.20Second-tier treatments Decompressive craniectomy33%36%29%33%80%33%100%0.16 Hypothermia22%25%71%25%0%0%0%0.29 Deep hyperventilation0%13%0%33%20%33%0%0.24 Barbiturates11%29%14%33%80%67%0%0.25 CSF drainage56%28%43%33%20%17%50%0.08*CSF* Cerebrospinal fluid*Note.* Table presents the percentage of participants within each geographic region that indicated that the first- or second-tier treatment was their general policy. Nagelkerke *R* ^2^ was derived from a logistic regression analysis with treatment (general policy yes/no) as the dependent variable and geographic region (categorical variable) as an independent variable. Nagelkerke *R* ^2^ represents the proportion of variance of the treatment variable that is accounted for by geographic regionNorthern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania

Discussion {#Sec17}
==========

We found substantial variation in the general approaches to ICP monitoring and treatment among 66 European neurotrauma centers. The majority of centers indicated that they would insert an ICP monitor in patients with severe TBI and head CT abnormalities. There was no consensus on other indications, however, nor was there consensus on peri-insertion precautions. The use of both first- and second-tier treatments for elevated ICP varied widely between centers and regions. We found that half of the centers employed a relatively aggressive ICP management approach, and the other half reported using a more conservative approach.

Strengths of this study include the high response rate (97%), the extensive development process of the questionnaire, and the comprehensive examination of both monitoring and treatment. In addition, because our survey was completed by centers that are currently collecting patient-level data for the CENTER-TBI study, the results of this study can be used directly as input for the CER analyses once the patient-level data become available. A limitation of our study is that the included centers represent a select group of European neurotrauma centers that are prominent in the field of neurotrauma care and research. Consequently, the picture obtained might be skewed. In addition, this study is dependent on perceived practices rather than on clinical data. Although we repeatedly emphasized confidentiality of results, we cannot exclude that some physicians presented (even subconsciously) a more favorable image or presented individual treatment preferences rather than the general policy in a center. This can be explored when individual patient-level data are available. A further limitation is that we asked for isolated general treatments but did not assess specific combinations. In clinical practice, however, different treatments are used simultaneously, and outcome might be determined by the combination of treatments provided rather than by one particular intervention.

The substantial variation in strategies for ICP management in our study was in line with previous survey studies in Europe \[[@CR12], [@CR13]\] and the United States \[[@CR15]\]. For example, Hesdorffer et al. \[[@CR15]\] found that mannitol, hypertonic saline, and hyperventilation were generally used in half of their centers. Guidelines have been proposed to reduce treatment variation in medicine \[[@CR19]\]. Although there has been an increase in protocolization of medicine and awareness of guidelines during the last decade, variation in ICP management may not have been reduced \[[@CR12], [@CR13]\]. Moreover, some participants claimed using treatments that are discouraged in the BTF guidelines. For example, one-fifth of the participants specified using barbiturates as first-tier treatment, whereas this is a second-tier treatment in the BTF guidelines \[[@CR20]\]. The discrepancy between BTF guidelines and reported policies indicates that there is little consensus among neurotrauma centers with respect to ICP management. This might be due to the relatively small evidence base underpinning the guidelines \[[@CR3]\].

Our study has several implications for the planned CER analyses. We found wide variation for most of the topics studied, which enables analyzing effectiveness of ICP management at the hospital level. Analyzing effectiveness at the hospital level might be especially useful for treatments that were indicated to be used "rarely," "sometimes," or "frequently" by the large majority of participants. For these treatments, patient characteristics play an important role, and these can dramatically confound conventional patient-level analyses \[[@CR4], [@CR5]\]. Caution should be applied, however, in the interpretation of the effects of treatments that are performed solely in some regions and not in others. For example, barbiturates are often used as first-tier treatment in the Baltic states and Eastern Europe but not in other regions. A harmful or beneficial effect could therefore also be attributed to other aspects of care in the particular regions rather than to barbiturate use itself. In principle, it is possible to adjust statistically for between-center differences other than the treatment variable of interest with a random-effects model with a random intercept for center. However, when correlations between the treatment variable of interest and other factors that differ between centers are strong, such as for the first-line use of barbiturates and region, this might not be sufficiently captured by the random-effects model. In such a case, differences in outcome cannot be attributed with certainty to the treatment under study.

On the basis of our findings, we recommend prioritizing the following topics for CER because of the feasibility of the center-level approach:ICP monitoring in patients with indications other than GCS ≤ 8 and CT abnormalitiesParenchymal vs. ventricular monitoring (with and without CSF drainage)Use of first-tier treatments for elevated ICP (including use of neuromuscular blocking agents, mannitol vs. hypertonic saline vs. mannitol + hypertonic saline, fentanyl vs. no fentanyl, fluid management)Use of second-tier treatments (including decompressive craniectomy vs. barbiturates vs. hypothermia)The effect of an aggressive ICP management policy vs. a more conservative approach

Conclusions {#Sec18}
===========

Substantial variation was found in the monitoring and treatment of patients with severe TBI and intracranial hypertension. These results indicate a lack of consensus among European neurotrauma centers and provide an important opportunity and necessity for CER to support the development of optimal treatment protocols for these severely affected patients.

Additional files
================

 {#Sec19}

Additional file 1:Provider profiling questionnaire. (PDF 672 kb) Additional file 2:Detailed results. (PDF 85 kb)

BTF

:   Brain Trauma Foundation

CENTER-TBI

:   Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury

CER

:   Comparative effectiveness research

CPP

:   Cerebral perfusion pressure

CSF

:   Cerebrospinal fluid

CT

:   Computed tomographic

EEG

:   Electroencephalogram

GCS

:   Glasgow Coma Scale

HS

:   Hypertonic saline

ICP

:   Intracranial pressure

ICU

:   Intensive care unit

INR

:   International normalized ratio

IV

:   Intravenous

PaCO~2~

:   Partial pressure of carbon dioxide

RCT

:   Randomized controlled trial

TBI

:   Traumatic brain injury

**Electronic supplementary material**

The online version of this article (doi:10.1186/s13054-017-1816-9) contains supplementary material, which is available to authorized users.

The authors thank all clinical staff and researchers at the CENTER-TBI sites for completing the provider profiling questionnaires.

***CENTER-TBI investigators and participants***

Hadie Adams^1^, Masala Alessandro^2^, Judith Allanson^3^, Krisztina Amrein^4^, Norberto Andaluz^5^, Nada Andelic^6^, Nanni Andrea^2^, Lasse Andreassen^7^, Audny Anke^8^,Anna Antoni^9^, Hilko Ardon^10^, Gérard Audibert^11^, Kaspars Auslands^12^, Philippe Azouvi^13^, Camelia Baciu^14^, Andrew Bacon^15^, Rafael Badenes^16^, Trevor Baglin^17^, Ronald Bartels^18^, Pál Barzó^19^, Ursula Bauerfeind^20^, Ronny Beer^21^, Francisco Javier Belda^16^, Bo-Michael Bellander^22^, Antonio Belli^23^, Rémy Bellier^24^, Habib Benali^25^, Thierry Benard^24^, Maurizio Berardino^26^, Luigi Beretta^27^, Christopher Beynon ^28^, Federico Bilotta^16^, Harald Binder^9^, Erta Biqiri^14^, Morten Blaabjerg^29^, Stine Borgen Lund^30^, Pierre Bouzat^31^, Peter Bragge^32^, Alexandra Brazinova^33^, Felix Brehar^34^, Camilla Brorsson^35^, Andras Buki^36^, Monika Bullinger^37^, Veronika Bučková^33^, Emiliana Calappi^38^, Peter Cameron^39^, Lozano Guillermo Carbayo^40^, Elsa Carise^24^, Keri Carpenter^41^, Ana M. Castaño-León^42^, Francesco Causin^43^, Giorgio Chevallard^14^, Arturo Chieregato^14^, Giuseppe Citerio^44,\ 45^, Maryse Cnossen^46^, Mark Coburn^47^, Jonathan Coles^48^, Jamie D. Cooper^49^, Marta Correia^50^, Amra Covic^51^, Nicola Curry^52^, Endre Czeiter^53^, Marek Czosnyka^54^, Claire Dahyot-Fizelier^24^, François Damas^55^, Pierre Damas^56^, Helen Dawes^57^, Véronique De Keyser^58^, Francesco Della Corte^59^, Bart Depreitere^60^, Shenghao Ding^61^, Diederik Dippel^62^, Kemal Dizdarevic^63^, Guy-Loup Dulière^55^, Adelaida Dzeko^64^, George Eapen^15^, Heiko Engemann^51^, Ari Ercole^65^, Patrick Esser^57^, Erzsébet Ezer^66^, Martin Fabricius^67^, Valery L. Feigin^68^, Junfeng Feng^61^, Kelly Foks ^62^, Francesca Fossi^14^, Gilles Francony^31^, Janek Frantzén^69^, Ulderico Freo^70^, Shirin Frisvold^71^, Alex Furmanov^72^, Pablo Gagliardo^73^, Damien Galanaud^25^, Guoyi Gao^74^, Karin Geleijns^41^, Alexandre Ghuysen^75^, Benoit Giraud^24^, Ben Glocker^76^, Pedro A. Gomez ^42^, Francesca Grossi^59^, Russell L. Gruen ^77^, Deepak Gupta^78^, Juanita A. Haagsma^46^, Ermin Hadzic^64^, Iain Haitsma^79^, Jed A. Hartings^80^, Raimund Helbok^21^, Eirik Helseth^81^, Daniel Hertle^28^, Sean Hill^82^, Astrid Hoedemaekers^83^, Stefan Hoefer^51^, Peter J. Hutchinson^1^, Kristine Asta Håberg^84^, Bram Jacobs^85^, Ivan Janciak^86^, Koen Janssens^58^, Ji-yao Jiang^74^, Kelly Jones^87^, Jean-Pierre Kalala^88^, Konstantinos Kamnitsas^76^, Mladen Karan^89^, Jana Karau^20^, Ari Katila^69^, Maija Kaukonen^90^, David Keeling^52^, Thomas Kerforne^24^, Naomi Ketharanathan^41^, Johannes Kettunen^91^, Riku Kivisaari^90^, Angelos G. Kolias^1^, Bálint Kolumbán^92^, Erwin Kompanje^93^, Daniel Kondziella ^67^, Lars-Owe Koskinen^35^, Noémi Kovács^92^, Ferenc Kálovits^94^, Alfonso Lagares^42^, Linda Lanyon^82^, Steven Laureys^95^, Martin Lauritzen^67^, Fiona Lecky^96^, Christian Ledig^76^, Rolf Lefering^97^, Valerie Legrand^98^, Jin Lei^61^, Leon Levi^99^, Roger Lightfoot^100^, Hester Lingsma^46^, Dirk Loeckx^101^, Angels Lozano^16^, Roger Luddington^17^, Chantal Luijten-Arts^83^, Andrew I.R. Maas^58^, Stephen MacDonald^17^, Charles MacFayden^65^, Marc Maegele^102^, Marek Majdan^33^, Sebastian Major^103^, Alex Manara^104^, Pauline Manhes^31^, Geoffrey Manley^105^, Didier Martin^106^, Costanza Martino^2^, Armando Maruenda^16^, Hugues Maréchal^55^, Dagmara Mastelova^86^, Julia Mattern^28^, Catherine McMahon^107^, Béla Melegh^108^, David Menon^65^, Tomas Menovsky^58^, Cristina Morganti-Kossmann^109^, Davide Mulazzi^38^, Manuel Mutschler^102^, Holger Mühlan^110^, Ancuta Negru^111^, David Nelson^82^, Eddy Neugebauer^102^, Virginia Newcombe^65^, Quentin Noirhomme ^95^, József Nyirádi^4^, Mauro Oddo^112^, Annemarie Oldenbeuving^113^, Matej Oresic^114^, Fabrizio Ortolano^38^, Aarno Palotie^91,\ 115,\ 116^, Paul M. Parizel^117^, Adriana Patruno^118^, Jean-François Payen^31^, Natascha Perera^119^, Vincent Perlbarg^25^, Paolo Persona^120^, Wilco Peul^121^, Nicolas Pichon^122^, Henning Piilgaard^67^, Anna Piippo ^90^, Sébastien Pili Floury^123^, Matti Pirinen^91^, Horia Ples^111^, Suzanne Polinder^46^, Inigo Pomposo^40^, Marek Psota^33^, Pim Pullens^117^, Louis Puybasset^124^, Arminas Ragauskas^125^, Rahul Raj^90^, Malinka Rambadagalla^126^, Veronika Rehorčíková^33^, Jonathan Rhodes^127^, Sylvia Richardson^128^, Samuli Ripatti^91^, Saulius Rocka^125^, Nicolas Rodier^122^, Cecilie Roe^129^, Olav Roise^130^, Gerwin Roks^131^, Pauline Romegoux^31^, Jonathan Rosand^132^, Jeffrey Rosenfeld^109^, Christina Rosenlund^133^, Guy Rosenthal^72^, Rolf Rossaint^47^, Sandra Rossi^120^, Tim Rostalski^110^, Daniel Rueckert^76^,Arcaute Felix de Ruiz^101^, Martin Rusnák^86^, Marco Sacchi^14^, Barbara Sahakian^65^, Juan Sahuquillo^134^, Oliver Sakowitz^135,\ 136^, Francesca Sala^118^, Paola Sanchez-Pena^25^, Renan Sanchez-Porras^28,\ 135^, Janos Sandor ^137^, Edgar Santos ^28^, Nadine Sasse ^51^, Luminita Sasu^59^, Davide Savo^118^, Inger Schipper^138^, Barbara Schlößer^20^, Silke Schmidt^110^, Annette Schneider^97^, Herbert Schoechl^139^, Guus Schoonman^131^, Frederik Schou Rico^140^, Elisabeth Schwendenwein^9^, Michael Schöll ^28^, Özcan Sir^141^, Toril Skandsen^142^, Lidwien Smakman^143^, Dirk Smeets^101^, Peter Smielewski^54^, Abayomi Sorinola^144^, Emmanuel Stamatakis^65^, Simon Stanworth^52^, Katrin Stegemann^110^, Nicole Steinbüchel^145^, Robert Stevens^146^, William Stewart^147^, Ewout W. Steyerberg^46^, Nino Stocchetti^148^, Nina Sundström^35^, Anneliese Synnot^149,\ 150^, József Szabó^94^, Jeannette Söderberg^82^, Fabio Silvio Taccone^16^, Viktória Tamás^144^, Päivi Tanskanen^90^, Alexandru Tascu^34^, Mark Steven Taylor ^33^, Ao Braden Te^68^, Olli Tenovuo ^69^, Guido Teodorani^151^, Alice Theadom^68^, Matt Thomas^104^, Dick Tibboel^41^, Christos Tolias^152^, Jean-Flory Luaba Tshibanda^153^, Cristina Maria Tudora^111^, Peter Vajkoczy^154^, Egils Valeinis^155^, Wim Van Hecke^101^, Dominique Van Praag^58^, Van Roost Dirk ^88^, Eline Van Vlierberghe^101^, Thijs vande Vyvere ^101^, Audrey Vanhaudenhuyse^25,\ 95^, Alessia Vargiolu^118^, Emmanuel Vega^156^, Jan Verheyden^101^, Paul M. Vespa ^157^, Anne Vik ^158^, Rimantas Vilcinis ^159^, Giacinta Vizzino ^14^, Carmen Vleggeert-Lankamp ^143^, Victor Volovici ^79^, Peter Vulekovic ^89^, Zoltán Vámos ^66^, Derick Wade ^57^, Kevin K.W. Wang ^160^, Lei Wang ^61^, Eno Wildschut ^41^, Guy Williams ^65^, Lisette Willumsen ^67^, Adam Wilson ^5^, Lindsay Wilson ^161^, Maren K.L. Winkler ^103^, Peter Ylén ^162^, Alexander Younsi ^28^, Menashe Zaaroor ^99^, Zhiqun Zhang ^163^, Zelong Zheng ^28^, Fabrizio Zumbo ^2^, Stefanie de Lange ^97^, Godard C.W. de Ruiter ^143^, Hugo den Boogert ^18^, Jeroen van Dijck ^164^, Thomas A. van Essen ^121^, Caroline van Heugten ^57^, Mathieu van der Jagt ^165^, Joukje van der Naalt ^851^

***Affiliations***

^1^ Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

^2^ Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy

^3^ Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

^4^ János Szentágothai Research Centre, University of Pécs, Pécs, Hungary

^5^ University of Cincinnati, Cincinnati, OH, United States

^6^ Division of Surgery and Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway

^7^ Department of Neurosurgery, University Hospital of Northern Norway, Tromsø, Norway

^8^ Department of Physical Medicine and Rehabilitation, University Hospital of Northern Norway, Tromsø, Norway

^9^ Trauma Surgery, Medical University Vienna, Vienna, Austria

^10^ Department of Neurosurgery, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands

^11^ Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France

^12^ Riga Eastern Clinical University Hospital, Riga, Latvia

^13^ Raymond Poincare Hospital, Assistance Publique -- Hopitaux de Paris, Paris, France

^14^ Neurointensive Care, Niguarda Hospital, Milan, Italy

^15^ Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

^16^ Department of Anesthesiology and Surgical-Trauma Intensive Care, Hospital Clinic Universitari de Valencia, Valencia, Spain

^17^ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

^18^ Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands

^19^ Department of Neurosurgery, University of Szeged, Szeged, Hungary

^20^ Institute for Transfusion Medicine (ITM), Witten/Herdecke University, Cologne, Germany

^21^ Department of Neurocritical Care, Innsbruck Medical University, Innsbruck, Austria

^22^ Department of Neurosurgery & Anesthesia & Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden

^23^ NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK

^24^ Intensive Care Unit, CHU Poitiers, Poitiers, France

^25^ Anesthesie-Réanimation, Assistance Publique -- Hopitaux de Paris, Paris, France

^26^ Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy

^27^ Department of Anesthesiology & Intensive Care, S. Raffaele University Hospital, Milan, Italy

^28^ Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany

^29^ Department of Neurology, Odense University Hospital, Odense, Denmark

^30^ Departments of Neuroscience and Nursing Science, Norwegian University of Science and Technology, Trondheim, Norway

^31^ Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France

^32^ BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Clayton, Australia

^33^ Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia

^34^ Department of Neurosurgery, Bagdasar-Arseni Emergency Clinical Hospital, Bucharest, Romania

^35^ Department of Neurosurgery, Umeå University Hospital, Umeå, Sweden

^36^ Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pecs, and Hungarian Brain Research Program, Pecs, Hungary

^37^ Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

^38^ Neuro-ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

^39^ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

^40^ Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain

^41^ Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands

^42^ Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

^43^ Department of Neuroscience, Azienda Ospedaliera Università di Padova, Padua, Italy

^44^ Neurointensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy

^45^ School of Medicine and Surgery, Università Milano Bicocca, Milan, Italy

^46^ Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands

^47^ Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany

^48^ Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

^49^ School of Public Health and Preventive Medicine, Monash University and The Alfred Hospital, Melbourne, Australia

^50^ Radiology/MRI Department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

^51^ Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany

^52^ Oxford University Hospitals NHS Trust, Oxford, UK

^53^ Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pecs, and Hungarian Brain Research Program (grant KTIA 13 NAP-A-II/8), Pecs, Hungary

^54^ Brain Physics Lab, Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

^55^ Intensive Care Unit, CHR Citadelle, Liège, Belgium

^56^ Intensive Care Unit, CHU de Liège, Liège, Belgium

^57^ Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK

^58^ Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium

^59^ Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy

^60^ Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium

^61^ Department of Neurosurgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

^62^ Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands

^63^ Department of Neurosurgery, Medical Faculty and Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

^64^ Department of Neurosurgery, Regional Medical Center dr Safet Mujić, Mostar, Bosnia and Herzegovina

^65^ Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

^66^ Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary

^67^ Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark

^68^ National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, NZ

^69^ Rehabilitation and Brain Trauma, Turku University Central Hospital and University of Turku, Turku, Finland

^70^ Department of Medicine, Azienda Ospedaliera Università di Padova, Padua, Italy

^71^ Department of Anesthesiology and Intensive Care, University Hospital of Northern Norway, Tromsø, Norway

^72^ Department of Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

^73^ Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain

^74^ Department of Neurosurgery, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

^75^ Emergency Department, CHU de Liège, Liège, Belgium

^76^ Department of Computing, Imperial College London, London, UK

^77^ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and Monash University, Clayton, Australia

^78^ Department of Neurosurgery, Neurosciences Centre & JPN Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India

^79^ Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands

^80^ Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA

^81^ Department of Neurosurgery, Oslo University Hospital, Oslo, Norway

^82^ Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden

^83^ Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

^84^ Department of Medical Imaging, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

^85^ Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands

^86^ International Neurotrauma Research Organisation, Vienna, Austria

^87^ National Institute for Stroke & Applied Neurosciences, Auckland University of Technology, Auckland, NZ

^88^ Department of Neurosurgery, University Hospital Ghent, Ghent, Belgium

^89^ Department of Neurosurgery, Clinical Centre of Vojvodina, Novi Sad, Serbia

^90^ Helsinki University Central Hospital, Helsinki, Finland

^91^ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

^92^ Hungarian Brain Research Program (grant KTIA 13 NAP-A-II/8), University of Pécs, Pécs, Hungary

^93^ Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

^94^ Department of Neurological & Spinal Surgery, Markusovszky University Teaching Hospital, Szombathely, Hungary

^95^ Cyclotron Research Center, University of Liège, Liège, Belgium

^96^ Emergency Medicine Research in Sheffield, Health Services Research Section, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

^97^ Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany

^98^ VP Global Project Management, Central Nervous System, ICON plc, Paris, France

^99^ Department of Neurosurgery, Rambam Medical Center, Haifa, Israel

^100^ Department of Anesthesiology & Intensive Care, University Hospitals Southhampton NHS Trust, Southhampton, UK

^101^ icoMetrix NV, Leuven, Belgium

^102^ Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sports Medicine, Witten/Herdecke University, Cologne, Germany

^103^ Centrum für Schlaganfallforschung, Charité -- Universitätsmedizin Berlin, Berlin, Germany

^104^ Intensive Care Unit, Southmead Hospital Bristol, Bristol, UK

^105^ Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA

^106^ Department of Neurosurgery, CHU de Liège, Liège, Belgium

^107^ Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK

^108^ Department of Medical Genetics, University of Pécs, Pécs, Hungary

^109^ National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Australia

^110^ Department Health and Prevention, University Greifswald, Greifswald, Germany

^111^ Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania

^112^ Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

^113^ Department of Intensive Care, Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands

^114^ Department of Systems Medicine, Steno Diabetes Center, Gentofte, Denmark

^115^ Analytic and Translational Genetics Unit, Department of Medicine, Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

^116^ Program in Medical and Population Genetics, The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA

^117^ Department of Radiology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium

^118^ Neurointenisve Care Unit, Department of Anesthesia & Intensive Care, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy

^119^ International Projects Management, ARTTIC, Munich, Germany

^120^ Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padua, Italy

^121^ Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Department of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands

^122^ Intensive Care Unit, CHU Dupuytren, Limoges, France

^123^ Intensive Care Unit, CHRU de Besançon, Besançon, France

^124^ Department of Anesthesiology and Critical Care, Pitié-Salpêtrière Teaching Hospital, Assistance Publique -- Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France

^125^ Department of Neurosurgery, Kaunas University of Technology and Vilnius University, Vilnius, Lithuania

^126^ Rēzekne Hospital, Rēzekne, Latvia

^127^ Department of Anaesthesia, Critical Care & Pain Medicine, NHS Lothian & University of Edinburgh, Edinburgh, UK

^128^ Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK

^129^ Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway

^130^ Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

^131^ Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands

^132^ The Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA

^133^ Department of Neurosurgery, Odense University Hospital, Odense, Denmark

^134^ Department of Neurosurgery, Vall d'Hebron University Hospital, Barcelona, Spain

^135^ Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany

^136^ University Hospital Heidelberg, Heidelberg, Germany

^137^ Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary

^138^ Department of Trauma Surgery, Leiden University Medical Center, Leiden, The Netherlands

^139^ Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria

^140^ Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark

^141^ Department of Emergency Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

^142^ Department of Physical Medicine and Rehabilitation, St. Olavs Hospital and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

^143^ Neurosurgical Cooperative Holland, Department of Neurosurgery, Leiden University Medical Center and Medical Center Haaglanden, Leiden and The Hague, The Netherlands

^144^ Department of Neurosurgery, University of Pécs, Pécs, Hungary

^145^ Universitätsmedizin Göttingen, Göttingen, Germany

^146^ Division of Neurosciences Critical Care, John Hopkins University School of Medicine, Baltimore, MD, USA

^147^ Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK

^148^ Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

^149^ Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

^150^ Cochrane Consumers and Communication Review Group, Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne, Australia

^151^ Department of Rehabilitation, M. Bufalini Hospital, Cesena, Italy

^152^ Department of Neurosurgery, King's College London, London, UK

^153^ Radiology/MRI Department, CHU de Liège, Liège, Belgium

^154^ Neurologie, Neurochirurgie und Psychiatrie, Charité -- Universitätsmedizin Berlin, Berlin, Germany

^155^ Pauls Stradiņš Clinical University Hospital, Riga, Latvia

^156^ Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France

^157^ Director of Neurocritical Care, University of California, Los Angeles, Los Angeles, CA, USA

^158^ Department of Neurosurgery, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

^159^ Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania

^160^ Department of Psychiatry, University of Florida, Gainesville, FL, USA

^161^ Division of Psychology, University of Stirling, Stirling, UK

^162^ VTT Technical Research Centre, Tampere, Finland

^163^ University of Florida, Gainesville, FL, USA

^164^ Department of Neurosurgery, The HAGA Hospital, The Hague, The Netherlands

^165^ Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands

Funding {#FPar1}
=======

Data used in the preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission Seventh Framework program (602150). In addition, TvE and WCP were supported by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study.

Availability of data and materials {#FPar2}
==================================

The datasets analyzed during the present study are available from the corresponding author on reasonable request.

MCC analyzed the data and wrote the manuscript. JAH designed Fig. [2a and b](#Fig2){ref-type="fig"}. MCC, MvdJ, , VV, TvE, SP, DN, AE, NS, GC, WCP, AIRM, DM, EWS, and HFL were involved in the development of the provider profiling questionnaires. All authors critically commented on the manuscript, and all authors read and approved the final version.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable. There are no patients included in present study, and participating centers have given consent by completing the questionnaires.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
